Emergent in $174m deal with AZ to expand manufacturing commitment 04-Aug-2020 By Ben Hargreaves Emergent will produce commercial scale drug substance for AZ’s potential vaccine for COVID-19.
Takeda sees ‘clear path’ to resolution of FDA warning letter 04-Aug-2020 By Nick Taylor Takeda aims to have the plant that manufactures drugs including Entyvio and leuprorelin ready for re-inspection within 12 months.
US government secures 100m doses of GSK and Sanofi vaccine for $2.1bn 03-Aug-2020 By Ben Hargreaves In return for capital for development and manufacturing scale-up help, Sanofi and GSK agree number of doses of potential COVID-19 vaccine.
Kite gets second CAR-T approval, 96% manufacturing success rate 30-Jul-2020 By Ben Hargreaves Kite becomes the first company to have two approved CAR-T treatments, with its second targeting rare form of lymphoma.
Hired & Retired: Taking care of business 29-Jul-2020 By Ben Hargreaves The industry plumps for business acumen, as companies seek to turn drug candidates from pipeline prospects to approved products.
AZ bets billions on Daiichi’s ADC therapy 28-Jul-2020 By Ben Hargreaves AZ agrees deal with Daiichi to co-develop a treatment in oncology, as part of its ADC strategy.
BD receives order for 177m syringes from US and Canada 27-Jul-2020 By Ben Hargreaves US and Canadian governments enter deal for needles and syringes to deliver potential COVID-19 vaccine.
Gilead continues equity stake strategy with $300m deal 23-Jul-2020 By Ben Hargreaves Gilead buys a stake in Tizona for its cancer immunotherapies, whilst holding the option to buy outright.
How much is COVID-19 vaccine worth? $2bn per 100m doses 22-Jul-2020 By Ben Hargreaves US government agrees a deal for 100m doses of potential vaccine, with option to take further 500m order.
The growth of the UK’s ‘golden triangle’ 22-Jul-2020 By Ben Hargreaves Research outlines the pace of growth in the UK’s biohub and how it will progress towards 2050.
Countries agree equitable COVID-19 vaccine access for 60% of globe 21-Jul-2020 By Ben Hargreaves WHO announces 165 countries look to ensure equal access to any vaccine for the novel coronavirus.
GSK acquires 10% stake in CureVac, partner on mRNA vaccines 20-Jul-2020 By Ben Hargreaves GSK pushes to broaden its infectious disease pipeline by agreeing development deal with CureVac for five candidates.
J&J to start P3 COVID-19 vaccine trials in September 20-Jul-2020 By Ben Hargreaves Moving on an accelerated timeline, the company seeks late September start date and to exceed 1bn doses by end of 2021.
IQVIA partners with AZ on COVID-19 vaccine clinical trials 16-Jul-2020 By Ben Hargreaves The two companies will work to set up clinical trials utilizing IQVIA’s Virtual Trial solutions.
Blackstone closes $4.6bn life sciences fund 14-Jul-2020 By Ben Hargreaves Blackstone Life Sciences completes first private fund to invest in treatments in late-stage development.
BeiGene launches $2bn share offering, backed by Amgen 13-Jul-2020 By Ben Hargreaves Chinese biotech plans to raise the sum as working capital, as it looks to progress its pipeline.
Sanofi signs €875m deal with Kiadis 13-Jul-2020 By Ben Hargreaves Sanofi looks to supplement its Sarclisa therapy with investigational treatment to treat multiple myeloma.
French biotech gets funding for universal flu and coronavirus vaccines 09-Jul-2020 By Ben Hargreaves Osivax receives public funding to apply its vaccine technology to protect against COVID-19 and future coronavirus strains.
Emergent signs $480m, five-year vaccine deal with J&J 07-Jul-2020 By Ben Hargreaves Emergent will provide contract development and manufacturing services for J&J’s potential COVID-19 vaccine.
J&J receives EU approval for Ebola vaccine 06-Jul-2020 By Ben Hargreaves The company becomes the second to receive approval, behind Merck, for its Ebola vaccine.
Takeda expands in gene therapy with $900m R&D deal 02-Jul-2020 By Ben Hargreaves Takeda signs R&D agreement with Carmine for the development of two non-viral gene therapies.
FDA says COVID-19 vaccine must be effective in half of recipients 01-Jul-2020 By Ben Hargreaves US FDA demands that vaccine must prevent or decrease severity in at least 50% of people receiving doses.
BioNTech receives $250m investment amid vaccine development 30-Jun-2020 By Staff Reporter June sees BioNTech secure hundreds of millions in investment to progress pipeline, including mRNA COVID-19 vaccine.
CSL Behring in $450m spend on hemophilia gene therapy 30-Jun-2020 By Ben Hargreaves The company buys the global rights to a gene therapy currently going through Phase III trials.
Gilead continues small deal spree 23-Jun-2020 By Ben Hargreaves Gilead buys a stake in Pionyr and holds the option to acquire the biotech outright.
Sanofi ties up $2.3bn Translate Bio agreement 23-Jun-2020 By Ben Hargreaves The partners extend an existing collaboration to develop mRNA vaccines against infectious diseases.
Biotech launches with $300m and ‘high precision’ cell therapies 23-Jun-2020 By Ben Hargreaves Orca Bio emerges with a manufacturing platform that it claims produces cell therapies with an ‘unprecedented turnaround time’.
Europe working to secure supply of J&J vaccine 22-Jun-2020 By Ben Hargreaves European Commission is working to guarantee access to J&J’s vaccine, as it bulks up vaccine supply, reports suggest.
Kite able to manufacture Yescarta in Europe after approval 16-Jun-2020 By Ben Hargreaves The cell therapy can now be produced for 4,000 patients per year in Europe.
AbbVie enters $3.8bn deal with Genmab 11-Jun-2020 By Ben Hargreaves The two companies will collaborate on Genmab’s lead bispecific antibody treatment and develop further candidates.
SUSupport expands to bring in Indian partner 10-Jun-2020 By Ben Hargreaves The Austrian startup provides its single-use equipment to PharmNXT in India.
AGC Biologics acquires commercial-scale facility from AstraZeneca 09-Jun-2020 By Ben Hargreaves The Colorado site currently possesses two 20,000L bioreactors, with the potential to add four more.
Lawsuit accuses CDMO of ‘blocking’ COVID-19 vaccine 08-Jun-2020 By Ben Hargreaves Inovio launches a lawsuit against VGXI, claiming that the CDMO has breached its manufacturing contract for vaccine candidate.
Investigation opened over biotech’s COVID-19 vaccine claim 03-Jun-2020 By Ben Hargreaves A law firm investigates Inovio over claims it developed a vaccine to COVID-19 within three hours.
Novavax expands COVID-19 vaccine manufacturing through acquisition 02-Jun-2020 By Ben Hargreaves Novavax buys Praha Vaccines and gains the capacity to produce over one billion doses of its COVID-19 vaccine candidate.
Gilead seals $2bn deal for Arcus’ pipeline 28-May-2020 By Ben Hargreaves Gilead signs 10-year deal with Arcus to gain access to its clinical and preclinical pipeline of immuno-oncology candidates.
Sanofi set to sell Regeneron shares worth $13bn 26-May-2020 By Ben Hargreaves Sanofi will sell close to 23 million shares of Regeneron stock, with plans to use the funds to support acqusitions.
Merck leaps into COVID-19 battle with three developments 26-May-2020 By Ben Hargreaves The company announces three deals on the same day, including an acquisition and two partnership deals against COVID-19.
Novartis’ gene therapy approved in Europe, talks ongoing on price 21-May-2020 By Ben Hargreaves The most expensive therapy in the world receives conditional approval in Europe.
UK injects funds into COVID-19 vaccine, puts citizens front of queue 19-May-2020 By Ben Hargreaves UK government will invest into an existing vaccine developed by the Oxford University and will speed up completion of a vaccine manufacturing center.
Sanofi retracts US-first stance on COVID-19 vaccine 18-May-2020 By Ben Hargreaves The French company bows to pressure from the French government to state that there will be no preferential supply to US of potential vaccine.
US outlines plan for readying coronavirus vaccine by start of 2021 18-May-2020 By Ben Hargreaves The US government provided details on ‘Operation Warp Speed’ and who will take leadership of the project.
FDA refuses to file BMS treatment over manufacturing concerns 14-May-2020 By Ben Hargreaves US FDA knocks back BMS and bluebird’s application for ide-cel, demanding further details on CMC portion of BLA.
Dyno launches with gene therapy partnership alongside Novartis 11-May-2020 By Ben Hargreaves The biotech emerges from stealth mode with two partnerships potentially worth in excess of $2bn.
Menarini set to acquire Stemline for $677m 07-May-2020 By Ben Hargreaves Menarini adds Stemline’s lead product, Elzonris, and its presence in the US with buyout deal.
Alexion in $1.4bn buyout for reversal agent 07-May-2020 By Ben Hargreaves Alexion agrees deal for Portola to gain access to its lead product, Andexxa, a treatment that counteracts anticoagulants.
How to prevent another COVID-19? ‘Invest in infrastructure’ 06-May-2020 By Ben Hargreaves CEO of Berkeley Lights talks about the company’s work to identify antibodies against COVID-19 and what the long-term picture looks like.
Sanofi insulin biosimilar close to European entrance 05-May-2020 By Ben Hargreaves Sanofi’s insulin aspart biosimilar receives positive opinion from the EMA’s CHMP.
Immunomedics closes $459m stock offering to launch drug, scale manufacture 04-May-2020 By Ben Hargreaves April saw the company add new CEO, receive approval for lead ADC drug, and launch a public offering of stock.
Sanofi receives FDA approval for quadrivalent meningococcal vaccine 28-Apr-2020 By Ben Hargreaves The company receives approval for MenQuadfi to prevent meningococcal disease.
